{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-050844","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.462513+00:00","generated_at":"2026-06-09T02:03:40.022526+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ocuphire appoints George Magrath as CEO effective Nov 1; awards 1M equity shares","bullets":["Dr. George Magrath appointed CEO and board member, effective Nov 1, 2023; succeeds interim CEO Rick Rodgers who remains on board.","Employment agreement: $575,000 base salary, 55% target bonus, 600,000 stock options and 400,000 RSUs as inducement grants.","Inducement plan increased by 2,000,000 shares to total 2,325,258 shares available for equity awards.","Magrath previously CEO of Lexitas Pharmaceutical Services; led acquisition and growth in ophthalmic CRO.","Committee composition changed effective Nov 15: Cam Gallagher chairs audit, James Manuso chairs compensation, Richard Rodgers chairs nominating."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-050844","json":"https://secwatch.observer/filing/0001140361-23-050844.json","markdown":"https://secwatch.observer/filing/0001140361-23-050844.md","text":"https://secwatch.observer/filing/0001140361-23-050844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123050844/0001140361-23-050844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123050844/ef20013742_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:03:40.022526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"032a556855","claim":"Dr. George Magrath was appointed as Chief Executive Officer at Opus Genetics, Inc..","evidence_excerpt":"On October 30 , 2023, the Board of Directors (the “Board” ) of Ocuphire Pharma, Inc. (the “Company” ) appointed Dr. George Magrath, age 39, as the Company’s Chief Executive Officer, effective as of November 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123050844/0001140361-23-050844-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}